Obsidian Therapeutics files prospectus for resale of up to 29,164,045 shares
Obsidian Therapeutics filed a prospectus covering the resale of up to 29,164,045 shares of common stock by selling stockholders.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.